Cytiva acquired the German software make GoSilico whose “powerfully innovative digital solution” will bring great value to Cytiva’s clients, who can use mechanistic models to improve their decisions, accelerate their process development and more quickly bring new therapies to market, notes Olivier Loeillot, VP, Cytiva. “GoSilico’s expert team and solution are a fantastic addition to Cytiva’s longtime strengths and capabilities in chromatography, process development, and overall bioprocessing,” he adds.

Thiemo Huuk, co-founder and co-CEO of GoSilico, says the company’s entire team is excited to join Cytiva.

“With Cytiva’s global presence and broad base of customers, our mechanistic modeling technology will reach more drugmakers, ultimately enabling a more robust process development and a more efficient path to bring new therapies to patients,” he adds.

Process development is an intense and time-consuming part of making a therapy. GoSilico’s simulation software is used to build digital twins of downstream processing. Compared to traditional methods, such as one factor at a time, which can take approximately 13 weeks, or design of experiments, which often takes approximately four weeks, the simulation can reveal how process parameters affect attributes. The result is a scalable and robust solution within about one week, a reduction in experiment materials and, more impactfully, more confident decision-making, according to Cytiva officials.

A survey commissioned by Cytiva and conducted by a third party global market research agency in December 2020, found that out of more than 100 respondents, approximately 2/3 said mechanistic modeling will enable them to get to market significantly faster, and more than 80% said it was the future of process development in chromatography.

GoSilico’s products will continue to be known as GoSilico ChromX and GoSilico DSPX for the immediate future and will be integrated into Cytiva immediately.